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Abstract
Portal vein thrombosis (PVT) is frequent in patients with liver cirrhosis and possible severe complications such as
mesenteric ischemia are rare, but can be life-threatening. However, different aspects of clinical relevance, diagnosis and
management of PVT are still areas of uncertainty and investigation in international guidelines. In this article, we elaborate
on PVT classification, geographical differences in clinical presentation and standards of diagnosis, and briefly on the current
pathophysiological understanding and risk factors. This review considers and highlights the pitfalls of the various
treatment approaches and prophylactic treatments. Finally, we review the controversial issue of clinical impact of PVT on
prognosis, especially considering liver transplantation and future perspectives.
Key words: portal vein thrombosis; liver cirrhosis; thrombophilia tests; low-molecular-weight heparin; transjugular intrahe-
patic portosystemic shunt; liver transplantation
Introduction
Portal vein thrombosis (PVT) in the general population is a rare
event, but it occurs relatively frequently in patients with liver
cirrhosis and its prevalence increases with the severity of the
disease. PVT can develop in the intra- or extrahepatic segments
of the portal vein and extend to the superior mesenteric vein
and/or the splenic vein. Moreover, PVT can progress from a par-
tial obstruction due to the presence of a thrombus in the lumen
of the vein to a complete blockade of portal venous blood flow.
In cirrhotic patients, the prevalence of PVT ranges between 0.6%
and 26% [1].
However, prevalence can vary depending on age, underlying
hepatic disease, velocity of portal venous blood flow and the
pro- versus anticoagulant status of the patient. In patients with
cirrhosis of Child-Pugh A and B, incidence of newly diagnosed
PVT after 1 and 5 years has been reported to be 4.6% and 10.7%,
respectively [2]. The relative risk of developing PVT in the pres-
ence of cirrhosis is increased more than seven-fold above the
risk observed in the general population, which is estimated to
be< 1.0% [3]. While patients with compensated cirrhosis are
rarely affected, PVT is frequently detected in advanced stages,
increasing up to 25% in liver-transplantation candidates and
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35% in cirrhotic patients with hepatocellular carcinoma (HCC)
[4]. However, in large studies including patients evaluated for
liver transplantation, 6.3% were diagnosed with PVT, in particu-
lar when cirrhosis was related to nonalcoholic steatohepatitis
[5]. Moreover, in patients with advanced cirrhosis and those
undergoing liver transplantation, a prevalence of between 5%
and 16% has been reported [6].
The signs and symptoms of PVT are very heterogeneous and
range from incidental diagnosis during diagnostic procedures
for unrelated reasons to severe complications due to intestinal
infarction or to the development of portal hypertension, such as
variceal bleeding that can occur from esophageal and/or gastric
fundic varices when splenic vein thrombosis is present.
Therefore, prognosis and treatment of PVT depend on the local-
ization, the degree of extension and the rapidity of develop-
ment, as well as risk factors for thrombosis and the stage of
chronic advanced liver disease.
The causal relationships and the clinical presentation are
often complex. As PVT may cause short-term as well as long-
term complications, correct management by adopting adequate
diagnostic and therapeutic measures is paramount. In this
review article, we discuss the classification, the symptoms and
signs, and the pathogenesis of PVT in cirrhosis, its clinical rele-
vance, diagnostic procedures and the main lines of management.
Definitions and classification
PVT refers to partial or complete occlusion by a blood clotting of
the portal vein trunk that can also include its right and left
intrahepatic branches. Extension to either superior mesenteric
or splenic veins or secondary intrahepatic portal branches is
possible.
However, the definitions show geographic differences. In
European guidelines, recent PVT has been defined as a recent
formation of a thrombus within the portal vein and/or right or
left branches [7]. In the absence of recanalization, the portal
venous lumen is obliterated, while porto-portal collaterals
develop, resulting in the cavernomatous transformation of the
portal vein, which might represent chronic PVT. The American
Association for the Study of Liver Diseases (AASLD), however,
defines acute PVT as the sudden formation of a thrombus
within the portal vein lumen, and chronic PVT when the
obstructed portion is replaced by a network of hepato-petal col-
laterals bypassing the thrombosed portion of the portal vein [8].
Although these definitions are easily interpreted and practice-
oriented, they are based purely on anatomic findings and are
limited by the fact that they only consider occlusion as defining
criteria, omitting any clinically significant consequences.
In patients with liver cirrhosis, PVT may be more accurately
defined as a clinical syndrome that presents either as an inci-
dental finding on abdominal imaging (performed for reasons
unrelated to PVT) or with highly variable signs and symptoms
resulting from portal vein obstruction and/or portal hyperten-
sion [9].
PVT in patients with cirrhosis has been shown to have little
influence on the course of liver disease, except for patients with
PVT at liver transplantation in whom 90-day mortality and graft
failure have been reported to be higher than in those without
PVT [10,11]. Moreover, non-progression or resolution has been
reported in up to 75% of patients. In general, PVT might be the
cause as well as the consequence of decompensation of cirrho-
sis or advanced liver disease.
To predict the presence of PVT in patients with cirrhosis,
some factors have been suggested, including Child B and C
stage, prior history of resolved PVT, associated pro-thrombotic
risk factors (major characteristics) and large portosystemic col-
laterals, HCC, history of systemic venous thrombosis, recent
abdominal surgical, endoscopic or invasive interventions and
portal flow velocity < 15 cm/sec [9].
To date, several classification systems for PVT have been
proposed but, despite their easy applicability, they failed to
assess PVT with precision, including site, degree, presentation
and functional relevance of the thrombosis [12–15]. Therefore, a
comprehensive new classification has been proposed that
includes not only an anatomical description, but also additional
information that will support the management decision process
[9]. The features of this new classification are presented in
Table 1.
The application of this new classification will enable a more
accurate assessment of patients diagnosed with this heteroge-
neous condition, while its validation in prospective studies will
allow refinements that will improve its relevance in the man-
agement of these patients.
Clinical presentation
In cirrhotic patients, PVT often is clinically unapparent and
diagnosed incidentally by ultrasound during routine follow-up
screening for HCC. In other cases, however, patients may
present with life-threatening complications. It is often difficult
to interpret specific symptoms, since the occurrence of PVT is
not necessarily causal for the deterioration, but might be super-
imposed on it. Therefore, clinical deterioration may be the con-
sequence of either a recent development of PVT or an episode
of decompensation due to progression of cirrhosis.
As mentioned above, PVT can be classified as recent or
chronic. Yet, this differentiation is based on clinical findings
and imaging rather than on temporal criteria. Although some
authors consider PVT as acute if symptoms developed less than
Table 1. New classification of portal vein thrombosis
Site of portal vein thrombosis
Type 1: Trunk only
Type 2: Branch only; 2a, one branch; 2b, both branches
Type 3: Trunk and branches
Degree of portal venous system occlusion
O: Occlusive: no flow visible in portal vein lumen on imaging/
Doppler study
NO: Non-occlusive: flow visible in portal vein lumen through imag-
ing/Doppler study
Duration and presentation
R: Recent (first time detected in previously patent portal vein, pres-
ence of hyperdense thrombus on imaging, absent or limited collat-
eral circulation, dilated portal vein at the site of occlusion)
Ch: Chronic (no hyperdense thrombus; previously diagnosed PVT on
follow-up, portal cavernoma and clinical features of portal
hypertension)
As: Asymptomatic
S: Symptomatic: features of acute PVT (with or without acute bowel
ischemia) or features of portal hypertension
Extent of portal vein system occlusion
S: Splenic vein
M: Mesenteric vein
SM: Both
Type and presence of underlying liver disease
Cirrhotic, non-cirrhotic liver disease, post-liver transplant, hepato-
cellular carcinoma, local malignancies and associated conditions
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60 days prior to hospitalization [16], this time duration is arbi-
trary and particularly difficult to verify.
In a study including patients with cirrhosis and cancer, the
patients presented with abdominal symptoms (including
abdominal pain, loss of appetite, nausea, vomiting and diar-
rhea) (63%), splenomegaly (63%), gastrointestinal (GI) hemor-
rhage (including hematemesis, rectal bleeding or melena) (53%),
fever (37%), ascites (32%) and weight loss (16%) [17]. Of these,
abdominal symptoms and fever were more frequent in acute
PVT, while gastroesophageal varices and hemorrhages occurred
more frequently in patients with chronic PVT.
In another study with 701 cirrhotic patients, 11.2% of
patients developed PVT and 57% of them presented with symp-
toms including GI bleeding (due to varices or portal hyperten-
sive gastropathy) or abdominal pain [18]. Acute abdominal pain
was frequently caused by intestinal ischemia or infarction due
to thrombotic involvement of the mesenteric veins. Moreover,
the majority of PVT occurred in patients with advanced cirrho-
sis, i.e. Child-Pugh stage B or C.
The clinical presentation of acute PVT varies in relation to
the extension of the thrombus. Involvement of the mesenteric
veins and its branches may lead to intestinal ischemia or infarc-
tion. As intestinal infarction has a mortality rate of up to 60%,
this may become fatal without rapid, correct diagnosis and
adequate treatment. An accurate diagnosis, however, is often
difficult, because the clinical manifestations are entirely non-
specific. The diagnosis of intestinal infarction must be consid-
ered when symptoms include persistent severe abdominal pain
or ileus, intestinal bleeding, ascites or organ failure. In the pres-
ence of lactic acidosis and increased inflammatory laboratory
findings (elevated C-reactive protein and leukocytosis), a surgi-
cal evaluation is mandatory, as bowel resection could be indi-
cated [7].
The clinical presentation of chronic PVT is often character-
ized by the consequences of portal hypertension, including gas-
troesophageal varices, GI bleeding, splenomegaly and
hypersplenism. Cirrhotic patients with PVT seem to be exposed
to a higher risk of variceal bleeding than cirrhotic patients with-
out PVT [1].
The clinical impact of PVT on the natural course of the dis-
ease has been the subject of many studies. Luca et al. studied
the association between PVT progression or regression and the
clinical outcome [19]. The luminal obstruction may be partial or
complete, depending on the severity of the thrombosis. In most
patients, PVT was partial at diagnosis, but thrombotic aspects
changed over time. Compared to patients with spontaneous
regression of PVT, thrombotic progression did not correlate
with an increase in mortality, episodes of hepatic decompensa-
tion and need for liver transplantation, at least in cirrhotic
patients with non-malignant PVT. Nery et al. found that, in
patients with cirrhosis, the development of PVT did not follow a
recent progression of liver disease and that there was no evi-
dence that the development of PVT was responsible for further
progression of liver disease [2]. A recent study confirmed that
PVT does not seem to worsen the prognosis of cirrhosis [20].
Diagnosis
The diagnosis of PVT is based on imaging techniques, including
ultrasound, computed tomography (CT) and magnetic reso-
nance imaging (MRI). In addition to direct demonstration of the
thrombus, further radiological aspects may indicate recent or
chronic onset, pathogenic mechanisms or possible
complications.
Doppler ultrasound is the first-choice diagnostic method, as
it is widely available, rapid and cheap. The thrombus can be
made visible as solid isoechoic or hyperechoic material within
the portal vein (Figure 1). In the early stages, however, the
thrombus may appear hypoechoic. With this method, it is pos-
sible to accurately evaluate whether the luminal obstruction is
partial or complete. Detection of a portal cavernoma (as multi-
ple serpiginous para-portal vessels) is highly suggestive for
chronic PVT. Portal hemodynamics, including the absence or
reduction in portal vein blood flow, can be assessed by color
Doppler ultrasound, pulsed wave ultrasound or, alternatively,
by contrast-enhanced ultrasound (CEUS). The latter can provide
more reliable results in detecting the absence of flow and in
patients with an extreme reduction in portal vein flow velocity
[21].
Contrast-enhanced CT or MRI are frequently used, particu-
larly in their portal venous phase, to complete the diagnosis
and extend imaging to the venous branches that may not be
easily accessed by ultrasound, and to detect possible complica-
tions, including intestinal infarction. Due to better represent-
ability of the mesenteric veins, these techniques have been
proven to be superior to Doppler ultrasound for the evaluation
of thrombotic extension within the portal venous system [8].
In patients with HCC, tumor invasion of the portal vein
should always be ruled out. Some characteristics, including
increased diameter of the portal vein ( 23 millimeters), intra-
thrombotic arterial neovascularization and enhancement of
endoluminal material during the arterial phase of contrast
injection (detected by CT scan or CEUS) seem to allow the differ-
entiation between benign and malignant PVT [22]. In addition to
Figure 1. Imaging findings of portal vein thrombosis. (A) An ultrasound study of
the liver of a female patient with liver cirrhosis Child-Pugh C, which revealed
echogenic thrombosis (arrow) in the lumen of portal vein trunk. Upon further
investigation, a hepatocellular carcinoma (HCC) was diagnosed. (B) Another
ultrasound study of the liver of a male patient with liver cirrhosis Child-Pugh B
also revealing echogenic thrombosis (arrow) in the lumen of the portal vein
trunk and intrahepatic right portal branch. Further investigation showed a
mutation in JAK2-V617F-gene. (C) A CT scan of a male patient with alcohol-
related liver cirrhosis and portal cavernoma (arrow). (D) A CT scan of a female
patient with chronic hepatitis C infection and development of portal vein
thrombosis due to HCC (arrow).
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CT imaging, CEUS appears to be a highly sensitive and specific
method in the diagnosis of neoplastic PVT in cirrhotic patients
[23].
Once PVT has been diagnosed, screening for pro-thrombotic
conditions should be considered. Abnormal results in the clas-
sic coagulation tests of prothrombin time and activated partial
thromboplastin time may be misleading in the evaluation of the
coagulation system, as they are inadequate for the assessment
of an imbalance of pro- and anticoagulant factors in cirrhotic
patients. This is due to a much higher sensitivity to the pro-
coagulant factors than to the anticoagulant factors (protein C,
protein S and anti-thrombin), thus predicting hypocoagulability
irrespective of possible pro-thrombotic conditions. Thrombin-
generation assays (TGA) and thromboelastometry appear to be
more suitable for the evaluation of the actual hemostasis in cir-
rhosis, as their results reflect pro- as well as anticoagulant fac-
tors. However, their use in the clinical setting remains
controversial and requires further evaluation [24].
Data on the benefits of screening for pro-thrombotic condi-
tions in patients with well-compensated cirrhosis and PVT
remain limited [8]. According to the European Association for
the Study of the Liver (EASL) clinical practice guidelines, screen-
ing for underlying thrombotic conditions in cirrhotic patients
with PVT should be considered (see below). All patients with
chronic PVT should be screened endoscopically for gastroeso-
phageal varices according to the current Baveno guidelines for
patients with cirrhosis [15].
Risk factors
The pathogenesis of PVT is multifactorial. Various pro-
thrombotic conditions, including local and systemic factors,
associated with PVT have been identified. Hypercoagulability,
reduction in portal blood flow and vascular endothelial lesions
are the main risk factors for development of PVT in cirrhosis, as
they are for venous thromboembolism in general (known as the
Virchow’s triad).
Due to thrombocytopenia and prolonged prothrombin time,
cirrhosis has long been considered to be associated with hemor-
rhagic coagulopathies. However, recent studies indicated a ten-
dency towards a more balanced coagulation in cirrhosis,
whereby pro-coagulant and anticoagulant factors maintain a
fragile equilibrium [25]. Hypercoagulability may be explained by
an increased ratio between elevated levels of factor VIII
(pro-coagulative effects) and decreased levels of protein C (anti-
coagulative effects) [24]. These imbalanced plasma levels of pro-
coagulant and anticoagulant factors are frequently detected in
cirrhotic patients and may lead to the development of PVT. The
recommended thrombophilia tests are:
• protein C activity;
• protein S activity;
• antithrombin activity;
• factor-V-Leiden gene (G1691A) mutation, APC ratio;
• prothrombin gene (G20210A) mutation;
• methylentetra-hydrofolate reductase C677T mutation;
• paroxysmal nocturnal hemoglobinuria;
• transglutaminase antibodies;
• Behcets disease clinical investigation;
• myeloproliferative disorders:
• JAK2 V617F mutation;
• Calreticulin exon 9 mutation;
• bone marrow biopsy;
• antiphospholipid syndrome:
• anticardiolipin antibodies;
• anti-beta 2GP1;
• lupus anticoagulant.
In more than two-thirds of cirrhotic patients with PVT,
inherited thrombophilic disorders can be detected. The pro-
thrombin gene 20210A mutation was found to be associated
with a more than five-fold increased risk of developing PVT [18].
Additionally, factor-V-Leiden mutation and methylentetra-
hydrofolate reductase C677T mutation are more frequently
detected in cirrhotic patients with PVT compared to those with-
out PVT [26]. However, in more recent studies, the causal rela-
tionship of these underlying thrombophilic disorders in the
pathogenesis of PVT is controversially discussed [2].
Portal hemodynamics play a critical role in the pathogenesis
of PVT in cirrhosis. Reduced portal blood flow results in an
increased intrahepatic vascular resistance due to cirrhotic
changes of the liver parenchyma and altered vascular reactivity.
The reduction in portal blood flow velocity to less than 15 cm/
sec on Doppler ultrasound has been identified as a significant
predictive factor of PVT [27]. The use of non-selective beta-
blockers may also contribute to the development of PVT by fur-
ther reduction in portal blood flow [28].
Additionally, the development of portosystemic collaterals
seems to negatively affect hemodynamic parameters in the por-
tal vein: flow volume of more than 400 ml/min and blood flow
velocity of more than 10 cm/sec in the largest collateral vessel
have been identified to correlate with the occurrence of PVT [29].
The development of PVT in cirrhotic patients seems to be
related to the severity of the disease, as it is more frequently
detected in advanced stages [18]. In a recent study, however,
the development of PVT in compensated cirrhosis was not
directly related to cirrhosis progression, nor did PVT itself seem
to aggravate the disease [30].
Vascular endothelial dysfunction may play a role in the
pathogenesis of PVT. There is evidence indicating that, in
patients with cirrhosis, markers of endothelial dysfunction,
including von Willebrand factor, p-selectin and isoprostanes,
are up-regulated [31], suggesting that endothelial cells in cirrho-
sis may favor the formation of thrombosis in the portal vein.
In addition to cirrhosis, neoplastic invasion of the portal vein is
a major cause of PVT. €Ogren et al. identified cancer as the cause of
PVT in two-thirds of cirrhotic patients [3]. In these patients, PVT
was related to invasion by primary hepatic cancer in one-third of
cases with a prevalence of 14%. Thus, there appears to be a risk of
developing PVT due to cirrhosis as well as hepatic cancer.
Inflammatory conditions, e.g. as a result of abdominal infec-
tions (spontaneous bacterial peritonitis, pancreatitis, cholecys-
titis, appendicitis, diverticulitis, etc.), have also been shown to
be associated with the development of PVT [32]. It is plausible,
although not yet demonstrated, that infectious conditions can
sustain pro-thrombotic states and therefore should be consid-
ered in the management of PVT in cirrhotic patients.
The influence of the etiology of cirrhosis on the development
of PVT is as yet insufficiently studied. However, neither viral
hepatitis B or C nor alcohol abuse was found to be predictive of
PVT. Intriguingly, in patients evaluated for liver transplantation,
PVT was detected, in particular when cirrhosis was related to
nonalcoholic steatohepatitis [5]. Further data are, however,
needed to confirm these findings.
Primary prophylaxis
The concept of prophylactic treatment of PVT in cirrhosis was
substantiated by a study showing that prophylactic doses of the
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low-molecular-weight heparin (LMWH) enoxaparin not only
prevents PVT without increasing the rate of bleeding in cirrhotic
patients, but also reduces bacterial translocation and liver
decompensation [33]. It has been suggested that the coagulation
cascade influences hepatic fibrogenesis via microthrombi and
tissue ischemia, which activate the hepatic stellate cells [34],
while enoxaparin reduced hepatic vascular resistance in experi-
mental models of cirrhosis by prevention of hepatic stellate cell
activation and decreased fibrogenesis [35]. Therefore, these
data strongly suggest that anticoagulation could have a signifi-
cantly more relevant impact not only on prevention of PVT, but
also on slowing down liver fibrosis. These clinical observations
deserve further investigation and advocate for primary prophy-
laxis using anticoagulants in cirrhotic patients.
As highlighted before, cirrhotic patients are not anticoagu-
lated by default as suggested by their increased international
normalized ratio. Therefore, thromboprophylaxis of cirrhotic
patients for prevention of deep vein thrombosis is indicated
similarly to recommendations in non-cirrhotic patients [36]. To
date, this concept has not yet been included in international
guidelines due to lack of randomized controlled trials (RCTs)
[15]. However, some of the available data suggest that prophy-
lactic PVT treatment may be indicated in cirrhotic
patients awaiting liver transplantation or after hepatic resection
[37,38].
Management
Aims and rationale
Therapy algorithms in current guidelines are based more on
expert opinion than on results from RCTs [7]. The main goal of
treatment is control and/or prevention of complications of PVT,
which are accomplished by restoring the portal blood flow and
prevention of thrombus extension. The latter is especially
important, since thrombosis of the superior mesenteric vein
might cause serious complications including mesenteric ische-
mia, which, in the setting of decompensated cirrhosis, could be
associated with extremely high mortality. However, while some
studies report that up to 70% of cases develop complete obstruc-
tion and/or extension to other splanchnic vessels [11,17,29,39],
others report PVT mostly to be non-occlusive, associated with a
high rate of spontaneous recanalization and without any influ-
ence on the clinical outcome [2]. However, patients with PVT
have an increased risk of failure to control variceal bleeding and
impaired survival after liver transplantation [39,40]. Therefore,
the rationale to treat and achieve early patency is controver-
sially discussed and the data published to date support different
opinions. In summary, recanalization of the portal vein is espe-
cially important for liver-transplantation candidates, as end-to-
end portal vein anastomosis is associated with better outcome
after liver transplantation compared to other surgical techni-
ques of portal vein reconstructions during liver transplantation
[41]. Moreover, in patients with inflammatory conditions and in
those at high risk of developing mesenteric ischemia, more
aggressive approaches might be indicated. While studies show
recurrent thrombosis after successful anticoagulation in almost
40% of cases after the anticoagulant is withdrawn [42], throm-
bus extinction occurs after transjugular intrahepatic portosyste-
mic shunt (TIPS) [43], and the TIPS procedure might be a feasible
secondary prophylaxis for PVT. However, data on this issue are
scarce and prospective studies are needed [44]. Nevertheless,
we suggest a step-wise escalation of treatment options, on
which we will elaborate below [7,15].
Anticoagulation
Patient selection for anticoagulation remains controversial.
According to the Baveno VI consensus, anticoagulation should
be considered in potential liver-transplantation candidates with
thrombosis of the main portal trunk or progressive PVT, with
the goal to facilitate liver transplantation and reduce post-
transplant morbidity and mortality [15]. For non-transplant can-
didates, no consensus has been found yet.
The data on safety and efficacy of anticoagulation are
mainly based on five studies including a total of 176 patients, in
most cases with partial PVT [37,39,42,45,46]. However, the pro-
portion of partial, occlusive, extensive and cavernomatous PVT
varied between the studies [44]. Under treatment, 8–50% of
patients showed complete thrombus resolution, while partial
resolution was observed in 33–45%. Thrombus progression was
found in less than 10%. Late initiation of anticoagulation after
onset of PVT (>6 months) correlated with recanalization failure
[42]. Most patients had a history of bleeding or high-risk varices
and received medical or endoscopic treatment prior to anticoa-
gulation. In a study in which LMWHs were administered, no
bleedings were observed [46]. However, another study reported
bleedings in 20% of patients, particularly variceal bleedings in
9% [42]. In all five studies combined, bleeding episodes occurred
in 5% [47]. Prolongation of treatment beyond 6 months was
associated with lower thrombus progression and recurrence
rate as well as a higher rate of recanalization [47].
Vitamin K antagonists (VKAs), LMWHs as well as direct-
acting oral anticoagulants (DOACs) are currently available for
the treatment of PVT. Data on LMWH and VKA demonstrated
their efficacy and safety [37,39,42,45,46]. However, long-term
effects in cirrhotic patients have not yet been systematically
evaluated. Nonetheless, VKA and LMWH bear some caveats.
While one advantage of VKA is its oral administration, associ-
ated with higher patient compliance, this leads to overestima-
tion of the Model for End Stage Liver Disease (MELD) score,
which is important for organ allocation in several systems (e.g.
Eurotransplant). In patients with bleeding episodes, a platelet
count <50  109/L and the use of VKA were the only factors
more frequently observed and suspected to be anticoagulation-
related [42].
Besides the beneficial pleiotropic effects of LMWH, subcuta-
neous administration might be a limitation, especially for long-
term use [47]. However, their effect minimally interferes with
the MELD score, while monitoring may be problematic due to
low antithrombin levels and difficult measurement conditions
for anti-factor-Xa in cirrhotic patients. Moreover, the accumula-
tion of LMWH in renal dysfunction, a frequent problem in
decompensated cirrhosis, may occur and lead to over-
anticoagulation [46,48]. Importantly, enoxaparin has been
studied in different doses (1.5 mg/kg vs 1.0 mg/kg per day) with
similar efficacy, but lower bleeding rates at lower dose [49], sug-
gesting that a dose adjustment in patients with cirrhosis might
be indicated.
DOACs represent an attractive alternative to VKAs and
LMWHs due to their oral administration and the fact that no
regular laboratory monitoring is required. Moreover, first data
show that use of DOAC is safe in cirrhotic patients [50,51].
However, the experience with DOACs is still limited and a
strong recommendation cannot be made until more studies
have become available.
In any case, the main concern when giving anticoagulants to
cirrhotic patients is the risk of inducing or aggravating a bleed-
ing episode, especially from varices. Screening endoscopy and
standard prophylaxis (primary or secondary) of variceal
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bleeding, as recommended by the Baveno guidelines, are neces-
sary prior to initiation of anticoagulation [15,49]. Importantly,
no increase in 5-day treatment failure or 6-week mortality was
reported in patients with upper GI bleeding under anticoagula-
tion [52]. Adverse events were oral bleeding, lower GI bleeding,
cerebral hemorrhage, vaginal bleeding, obscure GI bleeding and
surgical wound hemorrhage. No anticoagulation-related deaths
have been reported to date [37,42,45].
Interventional techniques
The endovascular approach in the management of PVT in cir-
rhotic patients aims at quickly restoring portal vein patency. A
plethora of techniques and access routes have been published [7].
The most common and studied approach is the TIPS with local
thrombus aspiration and thrombolysis. The reported success rates
on catheter-directed thrombolysis are excellent. However, there
are only limited data and a lack of RCTs considering this approach
[53]. Besides aiming at restoring portal vein patency by direct
catheter-directed lysis and removal of thrombus material, TIPS
also decompresses the portal system by decreasing portal pres-
sure and increasing portal flow velocity [54]. While the presence of
PVT has historically been considered a contraindication for TIPS,
technical improvements and increased expertise in experienced
centers does not support this attitude. Indeed, in select cases, TIPS
insertion can be successfully performed in patients with PVT [43].
In case of cavernomatous transformation, the technical procedure
is more challenging with a successful TIPS placement rate of 62–
74% [55,56]. Once TIPS can be placed, the recanalization rate is
excellent (up to 80% partially or completely restored patency) [43].
This effect is possibly independent of anticoagulation [43,57]. In
one study, residual thrombus was present in 77% of cases after
TIPS placement, while, 1 month after the TIPS procedure, 76% of
cases had complete resolution of thrombus. This suggests clot res-
olution due to increased portal venous flow. As these success rates
are similar to those of anticoagulation, TIPS may provide an alter-
native for patients with contraindications for anticoagulation,
severe symptoms or decompensation due to bleeding or ascites
[47]. Other authors suggest TIPS in cases of early non-response to
anticoagulation, extended/occlusive thrombus with high-risk vari-
ces or when symptomatic portal hypertension is present with PVT
[44]. Special attention should be given to liver-transplantation can-
didates as a higher rate of surgical complications by misplaced
TIPS stent has been described [58]. The shortest possible distance
into the portal vein and no extension of the stent into the inferior
vena cava (IVC) should be achieved. However, in most studies, the
outcome was not impacted [59–62]. In contrast, the largest study
to date showed improved graft and patient survival in TIPS
patients [61].
Surgical approach
The primary care consisting of medical and interventional
approaches for PVT as well as portal hypertension in general
has led to a steady decrease in surgical interventions in these
patients, resulting in a consequent decline in expertise in
portal-caval shunt surgery [63]. However, emergency surgical
intervention is still needed in cases of mesenteric ischemia and
refractory variceal bleeding when the TIPS procedure is not fea-
sible [7,15].
The surgical shunting procedures can be divided into three
groups: total shunt (portal-caval end-to-side; splenorenal side-
to-side (Cooley)), partial shunt (portal-caval side-to-side inter-
position (Sarfeh); mesocaval side-to-side interposition
(Drapanas); splenorenal proximal end-to-side (Linton)) and
selective shunt (mesorenal side-to-side; splenorenal distal end-
to-side (Warren); coronary-caval (Inokuchi)) (Table 2). The
choice of shunt procedure depends on liver function and the
extent of PVT. Usually, operative decompression should be per-
formed in patients with preserved liver function (Child-Pugh A
and compensated Child-Pugh B) due to high rates of mortality
(>50%) and hepatic encephalopathy in Child-Pugh C stage
[15,64]. Generally, partial and selective shunts have replaced the
total shunt due to its high rate of hepatic encephalopathy [65].
Prognosis
The effect of PVT on patients’ survival after liver transplanta-
tion is still controversial [66–68]. The extent of PVT might be
crucial to the post-liver-transplantation mortality [69,70].
Extensive PVT has been shown to be associated with higher
mortality after liver transplantation, while incidentally discov-
ered PVT during liver transplantation did not affect mortality
[67,70]. However, studies found that complete PVT impacts
short-term survival (3 months to 1 year), whereas long-term
survival does not differ between PVT and non-PVT groups
[41,71,72]. This effect might be due to the surgical techniques
available for portal anastomosis depending on the extent of
PVT. Survival rate in patients with non-anatomic anastomosis
(cavoportal hemitransposition, renoportal anastomosis, portal
vein arterialization) decreased, while in patients with physio-
logic anastomosis, survival is not impacted [41,73].
A study including 66,506 patients from the United Network
for Organ Sharing registry (UNOS) showed that liver-
transplantation waitin-list patients with PVT have lower mor-
tality than those without PVT [74]. Other recent studies using
data from the Scientific Registry of Transplant Recipients and
Organ Procurement and Transplantation Network (OPTN)
(nˆ22,291) and single-center experience reported that presence of
PVT does not increase mortality in waiting-list patients
[66,71,75].
Conclusions and future perspectives
PVT in liver cirrhosis is an important clinical evolution, which
could be an indication for or the cause of decompensation.
Taking into account the general benefits of anticoagulation
Table 2. Options for surgical shunt procedures
Total shunts Partial shunts Selective shunts
Portocaval End-to-side Side-to-side interposition (Sarfeh)
Mesocaval Side-to-side interposition (Drapanas)
Mesorenal Side-to-side
Splenorenal Side-to-side (Cooley) Proximal end-to-side (Linton) Distal end-to-side (Warren)
Coronary-caval Inokuchi
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with LMWHs in cirrhotic patients, this treatment might be pro-
vided more regularly and to many patients, even to those with-
out PVT but at risk of developing PVT. This, together with the
role of DOACs in PVT, must be validated in the future. However,
anticoagulation alone may not be sufficient to successfully treat
cirrhotic patients with PVT. Especially in some patients with
higher risk of developing complications and/or in candidates for
liver transplantation, a more aggressive treatment should be
considered, including interventional radiology. Overall, a signif-
icant amount of work remains to be done to improve the under-
standing and treatment of PVT and its underlying causes and
consequences.
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